X

Trial Profile

Targeting SPMS: Effect of teriflunomide treatment on microglial activation in an MS patient cohort at risk of progression. A [11C]PK11195 Brain PET study

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Teriflunomide (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use
Acronyms TERIPET

Most Recent Events

09 Apr 2024 Planned End Date changed from 1 Nov 2024 to 1 Dec 2024.
09 Apr 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
15 Mar 2023 Planned primary completion date changed from 1 Nov 2022 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com